Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization

Cancer Gene Therapy

Volumn 12, Issue 3, 2005, Pages 284-294

  Conrad, Charles ^a   Miller, C Ryan ^b   Ji, Yongjie ^a   Gomez Manzano, Candeleria ^a   Bharara, Suman ^c   McMurray, John S ^a   Lang, Frederick F ^a   Wong, Franklin ^d   Sawaya, Raymond ^a   Yung, W K Alfred ^a   Fueyo, Juan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d Department of Nuclear Imaging ^*  (United States)

Author keywords

24; Cytosine deaminase; Oncolytic virus; Suicide gene

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; ONCOLYTIC VIRUS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; E1A PROTEIN; PRIMER DNA;

ADENOVIRUS; ADENOVIRUS DELTA24 HYCD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CATALYSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG INDUCED DISEASE; ENZYME ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GLIOMA; GROWTH INHIBITION; HISTOPATHOLOGY; HYCD GENE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOISOTOPE DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; SURVIVAL; SYSTEMIC THERAPY; THIN LAYER CHROMATOGRAPHY; TISSUE SPECIFICITY; TRANSCRIPTION INITIATION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS REPLICATION; WESTERN BLOTTING; XENOGRAFT; COMPARATIVE STUDY; GENE VECTOR; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VIRUS;

ADENOVIRIDAE; SACCHAROMYCES CEREVISIAE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATOGRAPHY, THIN LAYER; CYTOSINE DEAMINASE; DNA PRIMERS; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; TRANSPLANTATION, HETEROLOGOUS; VIRUSES;

EID: 20044388552     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700750     Document Type: Article

References (27)

1. Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain tumors in the United States, 1992-1997. (2001) Available at http://www.cbtrus.org/reports.htm (accessed November 21, 2002).
2. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19:2-12.
3. Alemany R, Gomez-Manzano C, Balague C, et al. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res. 1999;252:1-12.
4. Henson JW, Schnitker BL, Correa KM, et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol. 1994;36:714-721.
5. Huang HJ, Yee JK, Shew JY, et al. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science. 1988;242:1563-1566.
6. Aghi M, Chou TC, Suling K, et al. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. 1999;59:3861-3865.
7. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol. 1998;16:444-448.
8. Boviatsis EJ, Park JS, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 1994;54:5745-5751.
9. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest. 2000;105:1169-1172.
10. Wildner O, Blaese RM, Morris JC, et al. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 1999;59:410-413.
11. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
12. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate to high-risk prostate cancer. Cancer Res. 2003;63:7497-7506.
13. Rogulski K, Wing MS, Paielli DL, et al. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther. 2000;11:67-76.
14. Bernt KM, Steinwaerder DS, Ni S, et al. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res. 2002;62:6089-6098.
15. Ueda K, Iwahashi M, Nakamori M, et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the Cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res. 2001;61:6158-6161.
16. Miller CR, Williams CR, Buchsbaum DJ, et al. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 2002;62:773-780.
17. Erbs P, Exinger F, Jund R. Characterization of the Saccharomyces cerevisiae FCY1 gene encoding cytosine deaminase and its homologue FCA1 of Candida albicans. Curr Genet. 1997;31:1-6.
18. Hamstra DA, Rice DJ, Fahmy S, et al. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther. 1999;10:1993-2003.
19. Whyte P, Williamson NM, Harlow E, et al. Cellular targets for transformation by the adenovirus E1A proteins. Cell. 1989;56:67-75.
20. Blanquicett C, Gillespie GY, Nabors LB, et al. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002;1:1139-1145.
21. Rubery ED, Newton AA. A simple paper chromatographic method for separation of methylated adenines and cytosine from the major bases found in nucleic acids. Anal Biochem. 1971;42:149-154.
22. Lal S, Lacroix M, Tofilon P, et al. An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg. 2000;92:326-333.
23. Kievit E, Bershad E, Ng E, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 1999;59:1417-1421.
24. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997;89:21-39.
25. Ueki K, Ono Y, Henson JW, et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 1996;56:150-153.
26. Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res. 2001;7:120-126.
27. Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003;95:652-660.